National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 24601-24602 [E8-9757]
Download as PDF
Federal Register / Vol. 73, No. 87 / Monday, May 5, 2008 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meetings
rfrederick on PROD1PC67 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group, Diabetes,
Endocrinology and Metabolic Diseases B
Subcommittee.
Date: June 12–13, 2008.
Open: June 12, 2008, 5 p.m. to 5:30 p.m.
Agenda: To review procedures and discuss
policy
Place: San Francisco Marriott, 55 Fourth
Street, San Francisco, CA 94103.
Closed: June 12, 2008, 5:30 p.m. to 9 p.m.
Agenda: To review and evaluate grant
applications.
Place: San Francisco Marriott, 55 Fourth
Street, San Francisco, CA 94103.
Closed: June 13, 2008, 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: San Francisco Marriott, 55 Fourth
Street, San Francisco, CA 94103.
Contact Person: John F. Connaughton, PhD,
Chief, Chartered Committees Section, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 753, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7797,
connaughtonj@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group, Kidney, Urologic and
Hematologic Diseases D Subcommittee.
Date: June 25–26, 2008.
Open: June 25, 2008, 8 a.m. to 8:30 a.m.
Agenda: To review procedures and discuss
policy.
VerDate Aug<31>2005
15:16 May 02, 2008
Jkt 214001
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Closed: June 25, 2008, 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Closed: June 26, 2008, 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Barbara A. Woynarowska,
PhD, Scientific Review Administrator,
Review Branch, Dea, NIDDK, National
Institutes of Health, Room 754, 6707
Democracy Boulevard, Bethesda, MD 20892–
5452, (301) 402–7172,
woynarowskab@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: April 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9758 Filed 5–2–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the Clinical Trials
Review Committee, June 30, 2008, 8:30
a.m. to July 1, 2008, 5 p.m., Pier 5 Hotel,
711 Eastern Avenue, Baltimore, MD
21202 which was published in the
Federal Register on April 22, 2008,
FRE8–8513.
The meeting dates were changed from
June 30–July 1, 2008 to June 23–24,
2008. Also, meeting location was
changed from Pier 5 Hotel to Sheraton
Columbia Hotel. The rest of the
information remains the same. The
meeting is closed to the public.
Dated: April 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9759 Filed 5–2–08; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
24601
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; Review of RFA DE–08–006
and RFA DE–08–007 Osteoimmunology—
Crosstalk between Immune System and Bone.
Date: June 3, 2008.
Time: 8 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza—Silver Spring, 8777
Georgia Avenue, Silver Spring, MD 20910.
Contact Person: Rebecca Wagenaar Miller,
PhD, Scientific Review Officer, Scientific
Review Branch, National Inst of Dental &
Craniofacial Research, National Institutes of
Health, 6701 Democracy, Rm 666, Bethesda,
MD 20892, 301–594–0652,
rwagenaa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: April 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9755 Filed 5–2–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
E:\FR\FM\05MYN1.SGM
05MYN1
24602
Federal Register / Vol. 73, No. 87 / Monday, May 5, 2008 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel, ‘‘Review of Clinical Trial
Planning Grants’’.
Date: May 29, 2008.
Time: 10 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 10401
Fernwood Road, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Kenneth E. Santora, PhD,
Scientific Review Officer, Scientific Review
Program, NIH/NIAID/DHHS, Room 3146,
6700B Rockledge Drive, MSC 7616, Bethesda,
MD 20892, 301–451–2605, ks216i@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9757 Filed 5–2–08; 8:45 am]
National Institutes of Health
rfrederick on PROD1PC67 with NOTICES
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Sickle Cell Disease Advisory
Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
15:16 May 02, 2008
Jkt 214001
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Aug<31>2005
Dated: April 25, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9638 Filed 5–2–08; 8:45 am]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
BILLING CODE 4140–01–M
Name of Committee: Sickle Cell Disease
Advisory Committee.
Date: June 2, 2008.
Time: 8:30 a.m. to 4 p.m.
Agenda: Discussion of Programs and
Issues.
Place: National Institutes of Health, 6701
Rockledge Drive, Conference Room 9112/
9116, Bethesda, MD 20892.
Contact Person: Robert B Moore, PhD,
Health Scientist Administrator, Blood
Diseases Program, Division of Blood Disease
and Resources, National Heart, Lung, and
Blood Institute, NIH, 6701 Rockledge Drive,
Room 10162, Bethesda, MD 20892, 301/435–
0050.
Information is also available on the
Institute’s/Center’s home page: https://
www.nhlbi.nih.gov/meetings/index.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Project: Community Mental Health
Services Block Grant Application
Guidance and Instructions, FY 2009–
2011 (OMB No. 0930–0168)—Revision
Sections 1911 through 1920 of the
Public Health Service Act (42 U.S.C.
300x through 300x–9) provide for
annual allotments to assist States to
establish or expand an organized,
community-based system of care for
adults with serious mental illnesses and
children with serious emotional
disturbances. Under these provisions of
the law, States may receive allotments
only after an application is submitted
and approved by the Secretary of the
Department of Health and Human
Services.
On January 28, 2008, SAMHSA
published a request for public comment
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
on its proposed guidance and
instructions to the States to guide
development of comprehensive State
applications/plans and implementation
reports for FY 2009–2011. Proposed
revisions to the guidance included:
(1) Streamlining the process for
reporting States’ use of the block grant
to support mental health transformation,
including narrowing from 20 to 6 the
number of transformation categories for
which States are asked to provide the
amount of funding that will be used to
support specific transformation
activities and limiting reporting to block
grant funds only.
(2) Reorganizing and consolidating
sections of the guidance to improve
readability and clarity and to reduce
redundancy.
(3) Eliminating Table 18 from the
Uniform Reporting System (URS) tables
that States must submit.
(4) Eliminating the requirement that
States complete a State-Level Reporting
Capacity Checklist for submission to the
State Data infrastructure Coordinating
Center.
SAMHSA received formal comments
from seven commenters. Most of the
comments supported the changes
described below, and several
commended SAMHSA for appointing a
Federal-State working group to address
concerns raised by the States regarding
the FY 2008 guidance and instructions.
A summary of the comments and
SAMHSA’s response is provided below.
Request for clarification regarding
reporting transformation expenditures
under Table C. Two commenters noted
that, while they supported the proposed
revisions to streamline the reporting of
transformation expenditures, their State
fiscal processes did not support tracking
and reporting expenditures in this
manner. One commenter requested
clarification that a State would ‘‘not be
held’’ to expenditure estimates provided
in the application.
The transformation expenditures
requested under Table C are an essential
component of the application guidance,
as they provide important information
to SAMHSA regarding States’ use of the
block grant to support mental health
transformation. SAMHSA clarifies that
the transformation expenditures
requested to be reported under Table C
of the application may be reported as
estimates if the State cannot provide
actual expenditures and that States are
not obligated to expend funds in the
categories indicated or to track and
justify their expenditures consistent
with these estimates. No change to the
guidance is needed to provide this
clarification.
E:\FR\FM\05MYN1.SGM
05MYN1
Agencies
[Federal Register Volume 73, Number 87 (Monday, May 5, 2008)]
[Notices]
[Pages 24601-24602]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-9757]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
[[Page 24602]]
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases, Special Emphasis Panel, ``Review of Clinical Trial
Planning Grants''.
Date: May 29, 2008.
Time: 10 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 10401 Fernwood Road,
Bethesda, MD 20817 (Telephone Conference Call).
Contact Person: Kenneth E. Santora, PhD, Scientific Review
Officer, Scientific Review Program, NIH/NIAID/DHHS, Room 3146, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD 20892, 301-451-2605,
ks216i@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: April 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-9757 Filed 5-2-08; 8:45 am]
BILLING CODE 4140-01-M